EMERYVILLE, Calif., Oct. 9, 2025 /PRNewswire/ — RegCell, Inc. a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the natural biology of regulatory T cells (Tregs), proudly announced…

EMERYVILLE, Calif., Oct. 9, 2025 /PRNewswire/ — RegCell, Inc. a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the natural biology of regulatory T cells (Tregs), proudly announced…